Financing Will Support SpectraWave’s Intracoronary Imaging Technology

February 3, 2021—SpectraWave, Inc. announced a $13.2 million Series A-2 financing to support completion of product development and regulatory filing for its flagship intracoronary imaging product. The privately held medical device company, based in Bedford, Massachusetts, was founded in 2017 to improve coronary artery disease outcomes with photonics.

Data from SpectraWave’s medical imaging platform aid interventional cardiologists during stent optimization and in their assessment of the patient’s risk for future adverse events. The platform combines two state-of-the-art technologies providing high-resolution plaque structure and content in coronary blood vessels.

With the new funds, SpectraWave will continue to scale the team, development, and operations ahead of a regulatory filing. The company has recently appointed additional experienced industry talent, including leaders in image analysis, clinical affairs, and regulatory and quality affairs, and has established a clinical advisory board.

The funding round is led by previous investor Deerfield Management and includes follow-on investment from previous unnamed seed investors.